AxoGen, Inc. (AXGN)

NASDAQ: AXGN · IEX Real-Time Price · USD
10.60
+0.15 (1.39%)
Feb 27, 2024, 9:43 AM EST - Market open
1.39%
Market Cap 446.36M
Revenue (ttm) 152.25M
Net Income (ttm) -23.24M
Shares Out 43.04M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,213
Open 10.54
Previous Close 10.45
Day's Range 10.59 - 10.60
52-Week Range 3.45 - 10.65
Beta 1.07
Analysts Strong Buy
Price Target 13.83 (+30.53%)
Earnings Date Mar 5, 2024

About AXGN

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Ms. Karen Zaderej
Employees 394
Stock Exchange NASDAQ
Ticker Symbol AXGN
Full Company Profile

Financial Performance

In 2022, AxoGen's revenue was $138.58 million, an increase of 8.81% compared to the previous year's $127.36 million. Losses were -$28.95 million, 7.27% more than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price forecast is $13.83, which is an increase of 30.53% from the latest price.

Price Target
$13.83
(30.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

13 days ago - GlobeNewsWire

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

24 days ago - GlobeNewsWire

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12.

5 weeks ago - GlobeNewsWire

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

7 weeks ago - GlobeNewsWire

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

7 weeks ago - GlobeNewsWire

Axogen Announces Promotions on Research and Development Team

ALACHUA, Fla. and TAMPA, Fla.

7 weeks ago - GlobeNewsWire

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen...

2 months ago - GlobeNewsWire

Axogen Announces Transition of Finance Team Leadership

Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth Nir Naor Appointed CFO to Replace Peter Mariani as Company Ali...

2 months ago - GlobeNewsWire

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

3 months ago - GlobeNewsWire

Axogen, Inc. Reports 2023 Third Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

4 months ago - GlobeNewsWire

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

4 months ago - GlobeNewsWire

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

ALACHUA, Fla. and TAMPA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

6 months ago - GlobeNewsWire

Axogen to Participate at Upcoming Investor Conferences

ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

6 months ago - GlobeNewsWire

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

6 months ago - GlobeNewsWire

Axogen, Inc. Reports 2023 Second Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

7 months ago - GlobeNewsWire

Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference

ALACHUA and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

7 months ago - GlobeNewsWire

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

7 months ago - GlobeNewsWire

Axogen to Participate at Jefferies Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

9 months ago - GlobeNewsWire

Axogen, Inc. Reports 2023 First Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

10 months ago - GlobeNewsWire

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

11 months ago - GlobeNewsWire

Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results

ALACHUA, Fla. and TAMPA, Fla., March 14, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

1 year ago - GlobeNewsWire

Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 year ago - GlobeNewsWire

Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

1 year ago - GlobeNewsWire

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

1 year ago - GlobeNewsWire

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

1 year ago - GlobeNewsWire